Ricin vaccine development

Current Topics in Microbiology and Immunology

Volumn 357, Issue , 2012, Pages 259-272

  Smallshaw, Joan E ^a   Vitetta, Ellen S ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Antibodies; Bioterroism; Recombinant vaccines; Ricin

Indexed keywords

ANTITOXIN; MONOCLONAL ANTIBODY; POLYGLACTIN; RECOMBINANT VACCINE; RICIN; RICIN ANTIBODY; RICIN TOXIN A; RICIN TOXIN A 1 33; RICIN TOXIN A 44 198; RICIN TOXIN A Y80A V76 M; RICIN TOXIN B; RIVAX; TOXOID; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL WARFARE; DRUG DETERMINATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; IMMUNIZATION; INCIDENCE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TOXIN ANALYSIS; TOXIN STRUCTURE;

ANIMALS; ANTIBODIES; ANTITOXINS; CHEMICAL WARFARE AGENTS; HUMANS; POST-EXPOSURE PROPHYLAXIS; RICIN; VACCINES; VACCINES, SYNTHETIC;

ANIMALIA;

EID: 84857862612     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/82_2011_156     Document Type: Article

References (50)

1. Audi J, Belson M, Patel M, Schier J, Osterloh J (2005) Ricin poisoning: a comprehensive review. JAMA 294:2342-2351
2. Baluna R, Vitetta ES (1999) An in vivo model to study immunotoxin-induced vascular leak in human tissue. J Immunother 22:41-47 (Pubitemid 29042289)
3. Baluna R, Coleman E, Jones C, Ghetie V, Vitetta ES (2000) The effect of a monoclonal antibody coupled to ricin A chain-derived peptides on endothelial cells in vitro: insights into toxin-mediated vascular damage. Exp Cell Res 258:417-424 (Pubitemid 30483520)
4. Baluna R, Ghetie V, Oppenheimer-Marks N, Vitetta ES (1996) Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells. Int J Immunopharm 18:355-361 (Pubitemid 27033232)
5. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES (1999) Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Natl Acad Sci USA 96:3957-3962 (Pubitemid 29169018)
6. Blakey DC, Thorpe PE (1986) Effect of chemical deglycosylation on the in vivo fate of ricin A-chain. Cancer Drug Deliv 3:189-196 (Pubitemid 17210800)
7. Carra JH, Wannemacher RW, Tammariello RF, Lindsey CY, Dinterman RE, Schokman RD, Smith LA (2007) Improved formulation of a recombinant ricin A-chain vaccine increases its stability and effective antigenicity. Vaccine 25:4149-4158 (Pubitemid 46635951)
8. Chanh TC, Hewetson JF (1995) Protection against ricin intoxication in vivo by anti-idiotype vaccination. Vaccine 13:479-485
9. Compton JR, Legler PM, Clingan BV, Olson MA, and Millard CB (2011) Introduction of a disulfide bond leads to stabilization and crystallization of a ricin immunogen. Proteins 79:1048-1060
10. Cook DL, David J, Griffiths GD (2006) Retrospective identification of ricin in animal tissues following administration by pulmonary and oral routes. Toxicology 223:61-70 (Pubitemid 43728628)
11. David J, Wilkinson LJ, Griffiths GD (2009) Inflammatory gene expression in response to sub-lethal ricin exposure in Balb/c mice. Toxicology 264:119-130
12. Eiklid K, Olsnes S, Pihl A (1980) Entry of lethal doses of abrin,ricin and modeccin into the cytosol of HeLa cells. Exp Cell Res 126:321-326 (Pubitemid 10041165)
13. Farah RA, Clinchy B, Herrera L, Vitetta ES (1998) The development of monoclonal antibodies for the therapy of cancer. Crit Rev Eukaryot Gene Expr 8:321-356 (Pubitemid 30152109)
14. Flexner S (1897) The histological changes produced by ricin and abrin intoxications. J Exp Med 2:197-216
15. Foxwell BM, Blakey DC, Brown AN, Donovan TA, Thorpe PE (1987) The preparation of deglycosylated ricin by recombination of glycosidase-treated A-and B-chains: effects of deglycosylation on toxicity and in vivo distribution. Biochim Biophys Acta 923:59-65 (Pubitemid 17229890)
16. Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted Toxins. Clin Cancer Res 6:326-334 (Pubitemid 30111447)
17. Franz DR and Jaax NK (1997) Ricin Toxin, in Textbook of Military Medicine, In: Zajtchuk R and Bellamy RF (eds) Office of the Surgeon General at TMM Publications, Borden Inst, Walter Reed Army Medical Center: Washington, DC p 631-642
18. Griffiths GD, Bailey SC, Hambrook JL, Keyte MP (1998) Local and systemic responses against ricin toxin promoted by toxoid or peptide vaccines alone or in liposomal formulations. Vaccine 16:530-535 (Pubitemid 28044171)
19. Griffiths GD, Bailey SC, Hambrook JL, Keyte M, Jayasekera P, Miles J, Williamson E (1997) Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal pulmonary dose of ricin toxin. Vaccine 15:1933-1939 (Pubitemid 27504690)
20. Griffiths GD, Lindsay CD, Allenby AC, Bailey SC, Scawin JW, Rice P, Upshall DG (1995) Protection against inhalation toxicity of ricin and abrin by immunisation. Hum Exp Toxicol 14:155-164
21. Griffiths GD, Phillips GJ, Bailey SC (1999) Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation. Vaccine 17:2562-2568 (Pubitemid 29314449)
22. Griffiths GD, Phillips GJ, and Holley J (2007) Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection. Inhal Toxicol 19:873-887 (Pubitemid 47237749)
23. Kende M, Yan C, Hewetson J, Frick MA, Rill WL, Tammariello R (2002) Oral immunization of mice with ricin toxoid vaccine encapsulated in polymeric microspheres against aerosol challenge. Vaccine 20:1681-1691 (Pubitemid 34169812)
24. Kende M, Del Giudice G, Rivera N, Hewetson J (2006) Enhancement of intranasal vaccination in mice with deglycosylated chain A ricin by LTR72, a novel mucosal adjuvant. Vaccine 24:2213-2221 (Pubitemid 43255166)
25. Kende M, Tan X, Wlazlowski C, Williams R, Lindsey C, Del Giudice G (2007) Enhancement of intranasal vaccination with recombinant chain A ricin vaccine (rRV) in mice by the mucosal adjuvants LTK63 and LTR72. Vaccine 25:3219-3227 (Pubitemid 46482754)
26. Legler PM, Brey RN, Smallshaw JE, Vitetta ES, and Millard CB Structure of RiVax, a recombinant ricin vaccine Journal? [submitted Acta Crystallographica Section D]
27. Marconescu PS, Smallshaw JE, Pop LM, Ruback SL, Vitetta ES (2010) Intradermal administration of RiVax protects animals from mucosal and systemic ricin intoxication. Vaccine 28:5315-5322
28. Marsden CJ, Knight S, Smith DC, Day PJ, Roberts LM, Phillips GJ, Lord JM (2004) Insertional mutagenesis of ricin A chain: a novel route to an anti-ricin vaccine. Vaccine 22:2800-2805 (Pubitemid 38900657)
29. Marsden CJ, Smith DC, Roberts LM, Lord JM (2005) Ricin: current understanding and prospects for an antiricin vaccine. Expert Rev Vaccines. 4:229-237 (Pubitemid 40525064)
30. McHugh CA, Tammariello RF, Millard CB, Carra JH (2004) Improved stability of a protein vaccine through elimination of a partially unfolded state. Protein Sci 13:2736-2743 (Pubitemid 39274641)
31. Neal LM, McCarthy EA, Morris CR, Mantis NJ (2011) Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA. Vaccine 29:681-689
32. Olsnes S (2004) The history of ricin, abrin and related toxins. Toxicon 44:361-370 (Pubitemid 39070638)
33. Olson MA, Carra JH, Roxas-Duncan V, Wannemacher RW, Smith LA, Millard CB (2004) Finding a new vaccine in the ricin protein fold. Protein Eng Des Sel 17:391-397 (Pubitemid 39093520)
34. Pincus SH, Eng L, Cooke CL, Maddaloni M (2002) Identification of hypoglycemia in mice as a surrogate marker of ricin toxicosis. Comp Med 52:530-533 (Pubitemid 36091703)
35. Pratt TS, Pincus SH, Hale ML, Moreira AL, Roy CJ, Tchou-Wong KM (2007) Oropharyngeal aspiration of ricin as a lung challenge model for evaluation of the therapeutic index of antibodies against ricin A-chain for post-exposure treatment. Exp Lung Res 33:459-481 (Pubitemid 350125561)
36. Roche JK, Stone MK, Gross LK, Lindner M, Seaner R, Pincus SH, Obrig TG (2008) Postexposure targeting of specific epitopes on ricin toxin abrogates toxin-induced hypoglycemia, hepatic injury, and lethality in a mouse model. Lab Invest 88:1178-1191
37. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT et al (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897 (Pubitemid 17041979)
38. Sausville EA and Vitetta ES (1997) Clinical studies with deglycosylated ricin A-chain immunotoxins in 'Monoclonal antibody-based therapy of cancer'. In: Grossbard ML (ed), Marcel Dekker Inc, Boston, vol 4 p 81-89
39. Schier JG, Patel MM, Belson MG, Patel A, Schwartz M, Fitzpatrick N, Drociuk D, Deitchman S, Meyer R, Litovitz T, Watson WA, Rubin CH, KieferM(2007) Public health investigation after the discovery of ricin in a South Carolina postal facility. Am J Public Health 97:S152-S157
40. Smallshaw JE, Vitetta ES (2010) A lyophilized formulation of RiVax, a recombinant ricin subunit vaccine, retains immunogenicity. Vaccine 28:2428-2435
41. Smallshaw JE, Firan A, Fulmer JR, Ruback SL, Ghetie V, Vitetta ES (2002) A novel recombinant vaccine which protects mice against ricin intoxication. Vaccine 20:3422-3427 (Pubitemid 35245826)
42. Smallshaw JE, Ghetie V, Rizo J, Fulmer JR, Trahan LL, Ghetie MA, Vitetta ES (2003) Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nature Biotech 21:387-391 (Pubitemid 36397658)
43. Smallshaw JE, Richardson JA, Pincus S, Schindler J, Vitetta ES (2005) Preclinical toxicity and efficacy testing of RiVax, a recombinant protein vaccine against ricin. Vaccine 23:4775-4784 (Pubitemid 41557328)
44. Smallshaw JE, Richardson JA, Vitetta ES (2007) RiVax, a recombinant ricin subunit vaccine, protects mice against ricin delivered by gavage or aerosol. Vaccine 25:7459-7469 (Pubitemid 47484003)
45. Soler-Rodriguez AM, Uhr JW, Richardson Vitetta ES (1992) The toxicity of chemically deglycosylated ricin A-chain in mice. Int J Immunopharmacol 14:281-291
46. Soler-Rodríguez AM, Ghetie MA, Oppenheimer-Marks N, Uhr JW, Vitetta ES (1993) Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. Exp Cell Res 206:227-234 (Pubitemid 23212940)
47. Spooner RA, Smith DC, Easton AJ, Roberts LM, Lord JM (2006) Retrograde transport pathways utilised by viruses and protein toxins. Virol J 3:26-35
48. Vitetta ES, Smallshaw JE, Coleman E, Jafri H, Foster C, Munford R, Schindler J (2006) A pilot clinical trial of a recombinant ricin vaccine in normal humans. Proc Natl Acad Sci USA 103:2268-2273 (Pubitemid 43271659)
49. Wong J, Korcheva V, Jacoby DB, Magun B (2007) Intrapulmonary delivery of ricin at high dosage triggers a systemic inflammatory response and glomerular damage. Am J Pathol 170:1497-1510 (Pubitemid 47339296)
50. Yan C, Rill WL, Malli R, Hewetson J, Naseem H, Tammariello R, Kende M (1996) Intranasal stimulation of long-lasting immunity against aerosol ricin challenge with ricin toxoid vaccine encapsulated in polymeric microspheres. Vaccine 14:1031-1038 (Pubitemid 26281290)